Business Updates During the three months ended September 30, 2017, we continued to grow our account base for GALLIPRANT with a majority of accounts reordering. The third quarter of 2017 included sequential increases for both GALLIPRANT product revenues, which we are selling in the United States in collaboration with Eli Lilly and Company, operating on behalf of its Elanco Animal Health division (“Elanco”), and GALLIPRANT licensing and collaboration revenue. Additionally, as of September 22, 2017, pursuant to the Collaboration, License, Development and Commercialization Agreement (the “Collaboration Agreement”), Elanco assumed ownership of regulatory filings and manufacturing responsibility for the applicable products based on licensed grapiprant rights and technology, including GALLIPRANT (collectively, the “Grapiprant Products”). We believe all residual matters related to the assumption by Elanco of manufacturing responsibility for Grapiprant Products will be concluded during the fourth quarter of 2017.
In the third quarter of 2017, for NOCITA, we continued to increase the number of accounts and the penetration within those accounts, with re-order rates continuing to increase compared to the second quarter of 2017.
As of late-October 2017, our third FDA-approved therapeutic, ENTYCE, is commercially available to veterinarians in the United States. ENTYCE is the only FDA-approved therapeutic for appetite stimulation in dogs.
We continued to advance our late-stage pipeline of therapeutic candidates for dogs and cats. Specifically, in October 2017, the AT-003 pivotal field effectiveness study in cats was submitted as part of the effectiveness technical section to the FDA’s Center for Veterinary Medicine (“CVM”) to support the intended NOCITA label expansion. Additionally, VetStem BioPharma Inc., our exclusive license partner responsible for development of AT-016, submitted the chemistry, manufacturing and controls (“CMC”) technical section to CVM in late- October 2017.
We believe that product sales for the remainder of 2017 will be composed primarily of product sales of NOCITA, GALLIPRANT, and ENTYCE, for which sales began in late-October 2017. We believe NO CITA and ENTYCE product sales in the remainder of 2017 will be dependent on our continuing efforts to commercialize the products. With respect to GALLIPRANT, in September 2017, Elanco assumed all manufacturing responsibilities for GALLIPRANT under the Collaboration Agreement, and we believe the transition of such responsibilities will be completed by December 31, 2017. See “ Manufacturing and Supply Chain” above for additional information. Future product sales of GALLIPRANT under the supply terms of the Collaboration Agreement will be limited to the agreed residual inventories sold to Elanco. At this time, we believe customer demand does not justify manufacturing additional BLONTRESS or TACTRESS. Therefore, both therapeutics will no longer be commercially available after mid-November 2017. We believe any future licensing and collaboration revenue in the remainder of 2017 will be substantially dependent on Elanco’s ability to successfully commercialize GALLIPRANT in accordance with the Elanco GALLIPRANT Agreements .
Under: Been on the sidelines for a bit holding (building) cash. Now that "BIGLEY" has rolled out the tax plan its time to jump in.
Dec 21, 2017 19:06:02 GMT -6
martyc: Looks like you are buying Msft again!
Dec 15, 2017 11:23:29 GMT -6
martyc: The news that Trump called Rupert to congratulate him sure seems to indicate that this is heading to approval
Dec 15, 2017 11:22:23 GMT -6
Under: DIS finally getting some traction.?
Dec 14, 2017 17:08:45 GMT -6
martyc: I took an entry level position in DIS. Will add eventually to overweight when it becomes clearer that the deal will go thru. Can't believe how well positioned they will be. 60% Hulu. 20% of content watched on NFLX they can pull. More in thread
Dec 14, 2017 11:05:16 GMT -6
Under: Great posts on $DIS
Dec 13, 2017 17:50:49 GMT -6
Under: $ROKU Citron on a war path.
Nov 28, 2017 15:11:20 GMT -6
Under: $HAS takeover bid for $MAT?
Nov 10, 2017 16:16:07 GMT -6
martyc: Not looking like the market will provide any discounted opp for SGMO. Call was just too professional and all signs indicate they are on a great path for commercialization. Happy with core but wish I had some trading shs
Nov 10, 2017 9:04:05 GMT -6
martyc: For anyone looking to find an entry point into SGMO, I'm almost hoping is sells off in next few days so I can add more. They are really clicking but the fact they haven't signed new deals might cause some to exit. Watching as I have room for trading shs
Nov 9, 2017 18:28:09 GMT -6
martyc: Been an interesting ride so far. I figured the Bears would be about this good but hoped the O wouldn't look so lame. Another building yr but still possible to get to 8-8 IMO
Nov 9, 2017 18:26:08 GMT -6
Under: whats up with your Bears this year Marty?
Nov 9, 2017 17:35:25 GMT -6
martyc: Hope you were long ROKU. I wanted to see Q first so missed out
Nov 9, 2017 7:08:53 GMT -6